Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo Inc. ( Daiichi Sankyo Europe, GmbH )
ClinicalTrials.gov Identifier:
NCT01101009
First received: April 7, 2010
Last updated: January 14, 2013
Last verified: January 2013

April 7, 2010
January 14, 2013
April 2010
November 2012   (final data collection date for primary outcome measure)
Change in central systolic blood pressure from baseline (Week 0, Visit 0) to Final Examination (Week 24, Visit 5) using last observation carried forward approach. [ Time Frame: Baseline to week 24 ] [ Designated as safety issue: No ]
Change in core systolic blood pressure from baseline (Week 0, Visit 0) to Final Examination (Week 24, Visit 5) using last observation carried forward approach. [ Time Frame: Baseline to week 24 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01101009 on ClinicalTrials.gov Archive Site
  • Changes in systolic and diastolic ambulatory blood pressure (mean of 24h, daytime and night-time) [ Time Frame: Baseline to week 24 ] [ Designated as safety issue: No ]
  • Changes in conventional mean sitting systolic and diastolic blood pressure measurement [ Time Frame: Baseline to 24 weeks ] [ Designated as safety issue: No ]
  • Incidence and profile of AEs separately by Run-in Phase and by double-blind Treatment Phase [ Time Frame: Run in phase (2 weeks) to end of study (24 weeks) ] [ Designated as safety issue: No ]
  • Number of responders at Final Examination defined as normalized or a decrease of systolic blood pressure by at least 20 mmHg or diastolic blood pressure by at least 10 mmHg in conventional BP measurements. [ Time Frame: Baseline to 24 weeks ] [ Designated as safety issue: No ]
  • Number of normalized at Final Examination (defined as blood pressure <140/90 mmHg or <130/80 mmHg in diabetics/chronic kidney disease, in conventional BP measurements. [ Time Frame: Baseline to 24 weeks ] [ Designated as safety issue: No ]
  • Changes in mean sitting systolic and diastolic blood pressure (BP) measurements from week 12 to Final Exam in patients with stabilized BP (BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) from Week 12 and Week 18. [ Time Frame: Week 12 to Week 18 or week 24 ] [ Designated as safety issue: No ]
  • Changes in Central Systolic Blood Pressure from week 12 to Final Examination in patients with stabilised BP (i.e. patients whose BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) between Week 12 and Week 18. [ Time Frame: Week 12 to week 18 or week 24 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-

Comparison of the combination of amlodipine with an angiotensin receptor blocker or an angiotensin converting inhibitor, on central arterial blood pressure in patients with hypertension and additional risk factors. This is a randomised, double-blind, double-dummy, multicenter study. The duration of active treatment 24 weeks.

The study, multi-center balanced, parallel group (two treatment arms), randomized, double-blind (double-dummy), non-inferiority study is designed to show non-inferiority of Sevikar® (olmesartan(OM)/amlodipine (AM)) 40/10 mg compared to the combination of Perindopril (PER) 8 mg plus Amlodipine 10 mg with regard to central systolic blood pressure lowering effect, using the change from baseline (Week 0) to final examination (Week 24).

Male and female Caucasians aged ≥ 40 years and <80 years with moderate to severe hypertension, defined by a systolic blood pressure (SBP) ≥ 160 and ≤ 200 or diastolic blood pressure (DBP) ≥ 100 and ≤ 115 mmHg for untreated patients, SBP ≥ 140 or DBP ≥ 90 mmHg for insufficiently pre-treated patients and SBP ≥ 130 mmHg or DBP ≥ 80 mmHg for insufficiently pretreated diabetics chronic kidney disease will be eligible for participation. In addition,three additional risk factors should be present.

During the course of the study three central blood pressure measurements (at randomization, at week 12 and at termination) will be performed with SphygmoCor ultrasound method. The conventional measurements with calibrated tensiometers (Omron) will be performed at each visit. Ambulatory blood pressure monitoring will be performed at randomisation.

The study starts with a 2-4 week run in phase. AM will be given as open-labelled 5 mg or 10 mg tablets, administered once daily. After randomization during the double-blind phase, study medication will comprise either OM/AM 40/10 mg or PER 8 mg (2x4 mg) plus AM 10 mg and will be administered once daily. Furthermore, open-label HCTZ 12.5 mg and 25.0 mg will be provided in tablets and administered once daily according to the treatment schedule.

The primary endpoint is the change in central SBP from baseline (Week 0, Visit 0) to final examination (Week 24, Visit 5) using Last Observation Carried Forward (LOCF) approach.

The study is conducted in approximately 15 centres in Spain. Depending on the previously administered drugs the run in phase is up to four weeks (Visits -2 and -1). Individual duration of active treatment (after randomization) will last 24 weeks (Visits 0-5). The total individual duration is 28 weeks.

A total of 518 patients (259 patients/arm) will be needed in the Per Protocol Set (PPS) for the confirmatory primary analysis using mean change from baseline (Week 0) to Final Examination assuming a drop out rate of 20% during Run-in Phase a total of 720 patients have to be screened in order to achieve 576 (288 patients/arm) randomised patients.

Assuming approximately 10% major protocol deviations, a total of 518 patients will remain in the PPS.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Hypertension
  • Drug: Perindopril + amlodipine + if necessary, hydrochlorothiazide
    Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
  • Drug: olmesartan/amlodipine + hydrochlorothiazide, if necessary.
    olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
  • Active Comparator: Perindopril+amlodipine
    Intervention: Drug: Perindopril + amlodipine + if necessary, hydrochlorothiazide
  • Active Comparator: Olmesartan/amlodipine
    Intervention: Drug: olmesartan/amlodipine + hydrochlorothiazide, if necessary.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
486
December 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • moderate to severe hypertension
  • 3 additional risk factors such as age > 55 (male), > 65 female, smoker, type 2 diabetes, obesity, cardiovascular disease, congestive heart failure, chronic kidney disease,
  • ability to give informed consent

Exclusion Criteria:

  • secondary or malignant hypertension
  • contraindication to any of the study drugs
  • Creatinine clearance level <40ml/min
  • treatment with more than 3 antihypertensive drugs
  • Myocardial infarction, percutaneous transluminal coronary angioplasty, cardiac bypass surgery < 6 month prior to start of the study,
  • unstable angina pectoris,
  • stroke, transient ischemic attack < 3 months prior to start,
  • Congestive heart failure NYHA II-IV,
  • clinically relevant concomitant diseases,
  • alcohol or drug abuse,
  • pregnancy or women of childbearing potential without contraceptive precaution,
Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01101009
DSE- SEV-02-09, 2009-012966-30
No
Daiichi Sankyo Inc. ( Daiichi Sankyo Europe, GmbH )
Daiichi Sankyo Europe, GmbH
Not Provided
Not Provided
Daiichi Sankyo Inc.
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP